|SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017|
Forward looking statements Some of the
statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including statements on the timing of additional data for the SER-287 Phase 1b study, the efficacy of
SER-287, expected interactions with the FDA regarding SER-287, and the application of SER-287 to other diseases. Such statements are subject to important factors, risks and uncertainties (such as those discussed under the caption "Risk Factors" in
the Company's Quarterly Report on Form 10-Q filed on August 3, 2017 and its other filings with the SEC) that may cause actual results to differ materially from those expressed or implied by such forward looking statements. Any forward looking
statements included herein represent our views as of today only. We may update these statements, but we disclaim any obligation to do so.
© Seres Therapeutics. All Rights Reserved.